about
BRAF mutations in hairy-cell leukemiaThe diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersPrognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Another piece of the AML puzzle.A comprehensive microarray-based DNA methylation study of 367 hematological neoplasmsSNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemiaEarly allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.The European LeukemiaNet: achievements and perspectives.Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 casesRecurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.Molecular diagnostics in acute leukemias.CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technologyComparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cellsClinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARAPrognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib TherapyDistinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics.High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.Gene expression profiling for the diagnosis of acute leukaemia.
P50
Q24609980-221DA49A-F047-4E76-8766-53EA3A21EE59Q24675681-980A27AC-EDD4-4112-8B9E-20250C8E5FD8Q27851417-4969E77E-71C3-4CC6-B406-718920A76B5EQ27851459-68A68701-92F2-4366-BC57-BA479132CB5FQ27851476-91B224C2-90F0-4492-9784-DF092C3554A0Q27851581-DCA84B57-A790-4E65-9C5E-2AAC6480C9BBQ27851642-B54BD550-C3CA-4238-83D6-A93CEA464F18Q27851909-928071F8-703A-45F6-BF79-6D7F84B76846Q27852046-76B314E7-8B52-4F6B-AD41-D65AD1D3DA1FQ27853066-428558E1-4220-4FF0-A98E-846DEC505B37Q30420638-30EC3B6E-6E4B-484B-AD5D-CF149DD55542Q33356686-FFB15CAD-85B4-4E84-BCC7-59194E99B20EQ33502760-8C094ED9-A1D0-4DEE-8A48-303C72D7A31DQ33517413-67B19687-A697-498F-AC76-2168A80859AFQ33613785-B52197F4-4968-410F-950B-66BD6B449AC0Q33829070-803A0C4D-C7B3-435A-B6A7-1D25DD5F2210Q34095608-5DD2E4C6-48A8-4F40-8FF3-9D13C72BCD32Q34167404-4CBFA5FB-E195-4973-9CAD-B631ECB0BF39Q34195440-F66870A0-C948-4282-AC8A-21A8E501653CQ34225646-1947B997-FD82-4A37-86E8-0522ABE58186Q34226368-F2FBF11B-F37B-4FE2-98C2-2D198764ACE7Q34248474-7115A801-C9FA-485B-B116-A45CD9D1F96AQ34295164-09F99956-7D0E-4ED9-A289-CD2C43115098Q34451619-B50454F7-09EA-474C-87F7-72ED78A07B7BQ34577037-96EC6168-B704-447D-9E59-9D143BEBF77AQ34655449-9ED45D0B-17FD-40EE-93BE-42F13602A15FQ35007333-562F28D6-8EE1-4996-884E-14EF77029225Q35018518-86D915CB-F1A9-47C4-8D46-90587DAE9F07Q35083685-DA2ABED7-5C47-4CF1-B317-DF13010A81F0Q35193722-82803E87-8EC2-4E90-9130-0F6ACAD7783CQ35596919-7BB776A2-B045-4ED5-91DB-579537F848A6Q35596960-9C34D1FD-AB46-403E-AA3B-F7AAD2F1FC41Q35667438-4F5B7B1F-3F09-441D-A5B6-57225AD77DDFQ36036294-24703F21-E1F9-4988-B5AC-4F5A49923F49Q36094707-E6501B0A-EEF4-4335-8030-8CF1D9DAE37EQ36366973-4DFE4DA1-8ECE-4394-A781-3497812AFD15Q36508333-CC7DAFD5-01EA-47B5-91A9-E61F03BB5B64Q36579076-BCBA4609-91D6-4DAE-BAD7-09BB06A0AAFDQ36579162-269B51D0-93AF-4EEF-838D-208655ECDF56Q36609901-C48382B1-9C5A-41DA-91CD-3323204B3E80
P50
description
researcher
@en
name
Claudia Haferlach
@ast
Claudia Haferlach
@en
Claudia Haferlach
@nl
type
label
Claudia Haferlach
@ast
Claudia Haferlach
@en
Claudia Haferlach
@nl
prefLabel
Claudia Haferlach
@ast
Claudia Haferlach
@en
Claudia Haferlach
@nl